Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE And RA Patients Following Single Target Dose In Phase 1 Trial
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978
Deep, dose-dependent B cell depletion observed in peripheral blood and tissue
Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen
Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10
Login to comment